Literature DB >> 22543921

Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Robert C Bast1, Steven Skates, Anna Lokshin, Richard G Moore.   

Abstract

More than 200,000 women undergo exploratory surgery for a pelvic mass in the United States each year and 13%-21% of pelvic lesions are found to be malignant. Individual reports and meta-analysis indicate better outcomes when cancer surgery is performed by gynecologic oncologists. Despite the advantages provided by more thorough staging and cytoreductive surgery, only 30%-50% of women with ovarian cancer are referred to surgeons with specialized training in the United States. Imaging, menopausal status and biomarkers can aid in distinguishing malignant from benign pelvic masses to inform decisions regarding appropriate referral. The risk of malignancy index (RMI) uses ultrasound, menopausal status and CA125 and has been utilized in the United Kingdom for two decades, providing sensitivity that has ranged from 71%-88% and specificity it from 97%-74% for identifying patients with malignant disease. Criteria have been established by the Society of Gynecology Oncology and American College of Obstetrics and Gynecology for referral to a gynecologic oncologist, but these have lower sensitivity and specificity than the RMI. Recently, two new algorithms have been developed to identify women at sufficiently high risk to prompt referral to a specialized surgeon. The OVA1 multivariate index incorporates imaging, menopausal status, CA125 and four other proteomic biomarkers. Use of OVA1 provides 85%-96% sensitivity at 28%-40% specificity depending upon menopausal status. The negative predictive value for women judged to be at low risk is 94%-96%. The risk of malignancy algorithm (ROMA) includes CA125, human epididymal protein 4 and menopausal status, but not imaging results. The ROMA has yielded 93%-94% sensitivity at 75% specificity with a negative predictive value of 93%-98%. In a direct comparison, ROMA has achieved greater sensitivity (94%) than the RMI (75%) at 75% specificity. OVA1 has not been compared directly to ROMA, but is likely to be as sensitive, but substantially less specific. Both algorithms have high negative predictive values 94%-98%. Although a difference in specificity should not affect patient outcomes, it could affect distribution of medical resources.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543921      PMCID: PMC3389992          DOI: 10.1097/IGC.0b013e318251c97d

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  37 in total

1.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Authors:  Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2010-03-24       Impact factor: 5.482

2.  The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Authors:  Martina Montagnana; Elisa Danese; Orazio Ruzzenente; Valentina Bresciani; Teresita Nuzzo; Matteo Gelati; Gian Luca Salvagno; Massimo Franchi; Giuseppe Lippi; Gian Cesare Guidi
Journal:  Clin Chem Lab Med       Date:  2011-02-03       Impact factor: 3.694

3.  HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

Authors:  Giuseppina Ruggeri; Elisabetta Bandiera; Laura Zanotti; Silvana Belloli; Antonella Ravaggi; Chiara Romani; Eliana Bignotti; Renata A Tassi; Germana Tognon; Claudio Galli; Luigi Caimi; Sergio Pecorelli
Journal:  Clin Chim Acta       Date:  2011-04-30       Impact factor: 3.786

4.  Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors.

Authors:  Frederick R Ueland; Christopher P Desimone; Leigh G Seamon; Rachel A Miller; Scott Goodrich; Iwona Podzielinski; Lori Sokoll; Alan Smith; John R van Nagell; Zhen Zhang
Journal:  Obstet Gynecol       Date:  2011-06       Impact factor: 7.661

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.

Authors:  Francis Jacob; Mara Meier; Rosmarie Caduff; Darlene Goldstein; Tatiana Pochechueva; Neville Hacker; Daniel Fink; Viola Heinzelmann-Schwarz
Journal:  Gynecol Oncol       Date:  2011-03-21       Impact factor: 5.482

7.  The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers.

Authors:  Zhen Zhang; Daniel W Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-20       Impact factor: 4.254

8.  Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.

Authors:  Yong Man Kim; Dong Hee Whang; Joonseok Park; Sung Hoon Kim; Shin Wha Lee; Hyun Ah Park; Mina Ha; Kyung-Hwa Choi
Journal:  Clin Chem Lab Med       Date:  2011-02-15       Impact factor: 3.694

9.  Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.

Authors:  Richard G Moore; M Craig Miller; Paul Disilvestro; Lisa M Landrum; Walter Gajewski; John J Ball; Steven J Skates
Journal:  Obstet Gynecol       Date:  2011-08       Impact factor: 7.661

10.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Authors:  T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

View more
  28 in total

Review 1.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

Review 2.  Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review.

Authors:  Suchitra Kumari
Journal:  Indian J Clin Biochem       Date:  2018-08-06

Review 3.  The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Authors:  Archana R Simmons; Keith Baggerly; Robert C Bast
Journal:  Oncology (Williston Park)       Date:  2013-06       Impact factor: 2.990

4.  A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

Authors:  Basil H Shadfan; Archana R Simmons; Glennon W Simmons; Andy Ho; Jorge Wong; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-11

5.  Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.

Authors:  M Polat; T Senol; E Ozkaya; G Ogurlu Pakay; M S Cikman; B Konukcu; M A Ozten; A Karateke
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

6.  Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Authors:  Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07-22       Impact factor: 4.254

Review 7.  Biomarkers in uterine leiomyoma.

Authors:  Gary Levy; Micah J Hill; Torie C Plowden; William H Catherino; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2012-11-29       Impact factor: 7.329

8.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327

Review 9.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

10.  Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Authors:  Steven J Skates; Michael A Gillette; Joshua LaBaer; Steven A Carr; Leigh Anderson; Daniel C Liebler; David Ransohoff; Nader Rifai; Marina Kondratovich; Živana Težak; Elizabeth Mansfield; Ann L Oberg; Ian Wright; Grady Barnes; Mitchell Gail; Mehdi Mesri; Christopher R Kinsinger; Henry Rodriguez; Emily S Boja
Journal:  J Proteome Res       Date:  2013-10-28       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.